Bruker Tops Estimates Bruker Scientific Instruments (BSI) delivered robust third quarter organic sales, led by increased government funding, strong NMR and MS sales, and timing of orders. Excluding currency and divestments, sales rose 9.2% to $366.6 million to account for 93% of revenues. System and aftermarket revenues grew roughly 7% and 16% organically to make […]
Despite indications that the global economy is continuing to slow, the outlook for sales growth within the instrument and lab product industry is positive. In late October, 15 industry executives completed the online IBO Business Climate Survey. The respondents were IBO subscribers and other solicited participants, each representing a unique company or business unit. The […]
In 2016, the top 20 pharmaceutical companies’ sales of products gained through mergers and acquisitions are expected to match those of products developed within the companies. By net present value, only 36% of phase III drugs were internally developed, whereas 31%, 31% and 2% of them were obtained through acquisitions of companies, in-licensing and acquisitions […]
The American Society of Clinical Oncology (ASCO) last month released its policy statement on genetic and genomic testing for cancer susceptibility, updated in light of advances in NGS. The statement made recommendations in several areas. For example, ASCO encouraged providers to create and institute plans to determine and respond to patients’ preferences for receiving information […]
Clinical and Agbio Markets Boost Affymetrix Q2 Sales Affymetrix second quarter sales grew 4.1%, 7.9% excluding currency, to $89.0 million. Organic growth was driven by agbio and clinical sales, which climbed 24% and roughly 20%, respectively. Overall, consumables and instrument sales grew 4.8% and 16.8%, to account for 86% and 4% of revenues, respectively. Service […]
Agilent Lowers Outlook Given currency and the discontinued NMR business (see IBO 3/31/15), which reduced sales growth by 7% and 1%, respectively, Agilent Technologies fiscal third quarter sales ending July 31 grew 0.5% to $1,014 million (see page 12). Despite the modest growth, sales were above analysts’ expectations. Core sales, which exclude the NMR business, […]
The consolidation of drug distributors is resulting in mergers among manufacturers of generic drugs. In the US, four companies buy the majority of generics, and generic-drug firms could merge to increase their abilities to negotiate with distributors. Merging may also help the companies face the costs of heightened examination of the industry by US regulators […]
This month, the US government issued a memo on updating the regulation of biotech products—products obtained through genetic engineering or organisms resulting from targeted gene manipulation. The update will address the fact that each federal agency dealing with biotech products (the EPA, FDA and USDA) currently has its own regulations and guidance, and that science […]
The 2013 market for prescription and over-the-counter drugs in Africa was $20.8 billion, more than quadrupling since 2003. One of the fastest-growing regions globally, the continent is expected to increase its GDP by 37% to $3.3 trillion between 2013 and 2020. Its pharmaceutical market is estimated to grow total $40–$60 billion by 2020, with a […]
Based on the top 500 pharmaceutical and biotechnology companies, the 2020 global market for prescription drugs is forecast at $987 billion, with a compound annual growth rate (CAGR) of 4.8% from 2014 to 2020. Sales in 2014 grew to $743 billion, up 2.8%, and total R&D increased 3.1% to $141.6 billion. R&D is forecast to […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
